SANGAMO THERAPEUTICS, INC: Important Update on Stock Status

Sangamo Therapeutics is a biotech company focused on genomic medicines, including gene therapy and gene editing. If you are following the company, it is important to understand the recent changes to their financial and market status, as these factors significantly impact the risk profile of the stock.

1. What happened?

As of May 5, 2026, Sangamo’s stock no longer trades on the Nasdaq. It has moved to the OTCQB Venture Market. This is an over-the-counter marketplace that generally has fewer reporting requirements and less oversight than major national exchanges.

2. Why did it happen?

The company failed to meet Nasdaq’s "minimum bid price" rule. To remain listed on the Nasdaq, companies must maintain a share price of at least $1.00. Sangamo’s stock remained below this threshold for an extended period, and they were unable to regain compliance within the grace period provided by the exchange.

3. Why does this matter for investors?

Moving to the OTCQB changes the landscape for trading this stock:

• Lower Visibility: Many institutional investors, such as pension funds and index funds, have mandates that prevent them from holding stocks that aren't listed on major exchanges. This can reduce demand for the shares.
• Less Liquidity: Trading volumes on the OTCQB are typically lower. You may find that the "spread"—the gap between the buy and sell price—is wider, which can make it more expensive or difficult to enter or exit a position.
• Higher Risk: This move reflects the company’s ongoing struggle to maintain its financial standing. The stock is now highly speculative and prone to significant price volatility.

4. Can they return to the Nasdaq?

Sangamo has requested a hearing with a Nasdaq panel scheduled for June 9, 2026. They intend to present a plan to regain compliance with listing requirements. It is important to note that there is no guarantee the panel will grant an extension, nor is there any certainty that the company will successfully relist.

5. The "Cash Crunch" Reality

Sangamo is currently in a precarious financial position. As of March 31, 2026, the company reported $27.6 million in cash. Based on their current burn rate, they anticipate this capital will be exhausted by the third quarter of 2026.

The company has been transparent that its future depends on securing a strategic partner or raising additional capital. Without a successful deal to bolster their cash reserves, they may be forced to scale back or stop operations entirely, which carries a risk of bankruptcy.

6. What should you consider before acting?

• Check your broker: If you own the stock, verify your broker’s rules regarding OTC securities. Some platforms restrict trading for these companies, which could limit your ability to sell or move your shares.
• Watch for catalysts: The company’s survival is tied to its progress with ST-920, their gene therapy for Fabry disease. Any news regarding a partnership or positive clinical developments is the most likely driver for the capital they need to survive.
• Expect volatility: Given the financial uncertainty and the upcoming June 9th hearing, you should expect extreme price swings.

Bottom Line: Sangamo is currently a "high-stakes" situation. The company is effectively in a race against time to secure funding. If you are considering an investment, ensure you are comfortable with the possibility of a total loss, as the path to recovery is narrow and highly dependent on external deals.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute professional financial advice. Sangamo faces significant financial pressure, and you could lose your entire investment. Always conduct your own thorough research and consult with a qualified professional before making any investment decisions.